| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6123332 | Journal of Infection | 2015 | 8 Pages |
Abstract
Linezolid was acceptable as initial empiric therapy for nocardiosis. Myelosuppression was a limiting factor, but not exclusive to patients on linezolid and could have been aggravated by concomitant use of other myelosuppressive drugs.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Oveimar De La Cruz, Lucio R. Minces, Fernanda P. Silveira,